ESTRO 2024 - Abstract Book

S2286

Clinical - Upper GI

ESTRO 2024

Immunohistochemical staining of EC primary tumor tissue showed heterogenous FAP-positivity in all specimen (7%- 45% of cells, IHC scoring (H-score) mean 36.3 (SD 24.6)). There was no correlation between high FAP-expression in the tissue and high FAP tracer uptake in the PET scans.

Conclusion:

We report first data on the use of PET with FAPI-46 for patients with EC who were scheduled to receive RT. Tumor uptake was high and not depending on FAP-expression in TME. Further, FAPI PET had relevant impact on management in this setting. Our data calls for prospective evaluation of FAPI PET to improve clinical outcomes of EC.

Keywords: Esophageal Cancer, FAPI, change of treatment